Document Detail


The Role of BCNU Polymer Wafers (Gliadel) in the Treatment of Malignant Glioma.
MedLine Citation:
PMID:  22440872     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
The 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; carmustine) polymer wafer (Gliadel) was developed for use in malignant glioma to deliver higher doses of chemotherapy directly to tumor tissue while bypassing systemic side effects. Phase III clinical trials for patients with newly diagnosed malignant gliomas demonstrated a small, but statistically significant, improvement in survival. However, the rate of complications, including an increase in cerebrospinal fluid leaks and intracranial hypertension, has limited their use. This article reviews the current data for use of BCNU wafers in malignant gliomas.
Authors:
Seema Nagpal
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-2-18
Journal Detail:
Title:  Neurosurgery clinics of North America     Volume:  23     ISSN:  1558-1349     ISO Abbreviation:  -     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-3-23     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9008004     Medline TA:  Neurosurg Clin N Am     Country:  -    
Other Details:
Languages:  ENG     Pagination:  289-295     Citation Subset:  -    
Copyright Information:
Copyright © 2012 Elsevier Inc. All rights reserved.
Affiliation:
Division of Neuro-Oncology, Department of Neurology, Stanford Advanced Medicine Center, 875 Blake Wilbur Drive, CC2221, Stanford, CA 94305-5826, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pseudoprogression and Treatment Effect.
Next Document:  Alternative Chemotherapeutic Agents: Nitrosoureas, Cisplatin, Irinotecan.